Biomea Fusion Q3 net loss $22.9M, cash $133.8M; advances BMF-219 into KRAS solid tumors and T2D

Biomea Fusion, Inc.

2022-Q3 EPS reported -$1.93 revenue$1,235,000,000

Net loss $22.9M in Q3 2022 ($12.6M in Q3 2021); cash & investments $133.8M vs $175.7M year-end 2021.
BMF-219 Phase I COVALENT-101 enrolling four liquid tumor cohorts; Cohort I at Dose Level 3, no DLTs; initial data H1 2023.
COVALENT-102 (Phase I/Ib) initiated for KRAS-mutated solid tumors (NSCLC, CRC, PDAC) under FDA clearance Oct 2022.
COVALENT-111 (Phase I/II) dosed first type 2 diabetes patient; healthy volunteer portion completed with no safety signals.
Expect IND submissions for BMF-500 (FLT3 inhibitor) and BMF-219 in T2D in H1 2023 and year-end 2022, respectively.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biomea Fusion, Inc. reported the quarter ended September 30, 2022 results: net income net loss attributable to common stockholders of $22.9 million.

Period: the quarter ended September 30, 2022
Net income: net loss attributable to common stockholders of $22.9 million
Result: reported results

Exact text from the filing

On November 7, 2022, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Biomea Fusion, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.